Complementary and Alternative Medicine and gastrointestinal diseases

Current Opinion in Gastroenterology

Volumn 16, Issue 2, 2000, Pages 188-196

  Haas, Laurie ^a   McClain, Craig ^a,b   Varilek, Gary ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b Division of Digestive Diseases and Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000685714     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200003000-00016     Document Type: Article

References (54)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL: Unconventional medicine in the United States: prevalence, costs, and pattern of use. N Engl J Med 1993, 328:246-252.
2. Eisenberg DM, Davis RB, Etner SL, et al.: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998, 280:1569-1575. This is an excellent overview of current CAM use in the USA reported by an experienced research group.
3. Meagher EA, Barry OP, Burke A, Lucy MR, Lawson JA, Rokach J, FitzGerald GA: Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 1999, 104:805-813.
4. 4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology 1995, 22:1474-1481.
5. Hill DB, Devalaraja R, Joshi-Barve S, Barve S, McClain CJ: Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem 1999, 32:1-8.
6. Colell A, Garcia-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rodes J, et al.: Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Hepatology 1997, 26:699-708.
7. Pena LR, Hill DB, McClain CJ: Treatment with glutathione precursor decreases cytokine activity. JPEN 1999, 23:1-6.
8. Sanchez-Gongora E, Ruiz F, Mingorance J, An W, Corrales FJ, Mato JM: Interaction of liver methionine adenosyltransferase with hydroxyl radical. FASEB J 1997, 11:1013-1019.
9. Chawla RK, Watson WH, Jones DP: Effect of hypoxia on tRNA methyltransferase and DNA methylation: similarities to effect of methyl deficient diets. J Cell Biochem 1996, 61:72-80.
10. Mato JM, Camara J, de Paz F, Caballeria L, Coll S, Caballero A, et al.: S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999, 30:1081-1089.
11. Chawla R, Watson W, Eastin C, Lee E, Schmidt J, McClain CJ: S-adenosylmethionine (AdoMet) deficiency and tumor necrosis factor (TNF) in lipopolysaccharide (LPS) induced hepatic injury. Am J Physiol 1998, 275:G125-G129. Animal model of liver injury demonstrating the interactions of SAMe (Adomet) and tumor necrosis factor (TNF). SAMe was able to attenuate endotoxin, and TNF induced hepatotoxicity.
12. Watson WH, Zhao Y, Chawla RK: S-adenosylmethionine attenuates the lipopolysaccharide-induced expression of the gene for tumor necrosis factor α. Biochem J 1999, 342:21-25.
13. Lieber CS, Leo MA, Aleynik SI, Aleynik MK, DeCarli LM: Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcohol Clin Exp Res 1997, 21:375-379.
14. Luper S: A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 1998, 3:410-421.
15. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al.: Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatology 1989, 9:105-113.
16. Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, et al.: Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatology 1998, 28:615-621.
17. Yang F, de Villiers WJS, McClain CJ, Varilek GW: Green tea polyphenols block endotoxin-induced tumor necrosis factor-α production and lethality in a murine model. J Nutr 1998, 128:2334-2340.
18. Schuppan D, Jia J-D, Brinkhaus B, Hahn EG: Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999, 30:1099-1104. Current overview of both potential therapeutic and hepatotoxin effects of herbal products.
19. Drossman DA, Ritcher JE, Talley NJ, et al.: Functional gastrointestinal disorders: diagnosis, pathophysiology and treatment. McLean, VA: Degnon and Associates; 1994:115-173.
20. Drossman DA, Li Z, Andruzzi E, et al.: U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993, 38:1569-1580.
21. Smart HL, Mayberry JF, Atkinson M: Alternative medicine consultations and remedies in patients with irritable bowel syndrome. Gut 1986, 27:826-828.
22. Manning AP, Heaton KW, Harrey RF: Wheat fibre and irritable bowel syndrome: a controlled trial. Lancet 1977, 27:417-418.
23. Lucey MR, Clark ML, Lowndes JO, et al.: Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled cross over study. Gut 1987, 28:221-225.
24. Golechha AC, Chadda VS, Chadda S, et al.: Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind cross over study). J Assoc Phys India 1982, 30:353-355.
25. Francis CY, Whorwell PJ: Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994, 344:39-40.
26. Pittler MH, Ernst E: Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. Am J Gastro 1998, 93:1131-1135. This is an excellent meta-analysis of existing trials of peppermint oil and its use for IBS.
27. Bensoussan A, Talley NJ, Hing M: Treatment of irritable bowel syndrome with Chinese herbal medicine (a randomized controlled trial). JAMA 1998, 280:1585-1589. This study provides a new therapeutic option for patients with IBS.
28. Yadav SK, Jain AK, Tripathi N, et al.: Irritable bowel syndrome: therapeutic evaluation of indigenous drugs. Indian J Med Res 1989, 90:496-503.
29. Yamahara J, Huang QR, Li YH, et al.: Gastrointestinal motility enhancing effect of ginger and its active constituents. Chem Pharm Bull (Tokyo) 1990, 38:430-431.
30. Verhoef MJ, Sutherland LR: Outpatient health care utilization of patients with inflammatory bowel disease. Dig Dis Sci 1990, 35:1276-1280.
31. Moser G, Tillinger W, Sachs G, Maier-Dobersberger T, Wyatt J, Vogelsang H, et al.: Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res 1996, 40:503-509.
32. Hilsden RJ, Scott CM, Verhoef MJ: Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol 1998, 93:697-701.
33. Sharon P, Setnson, WF: Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984, 86:453-460.
34. Lee TH, Austen F: Arachidonic acid metabolism by the 5-lipoxygenase pathway, and the effects of alternative dietary fatty acids. Adv Immunol 1985, 39:145-175.
35. Stenson WF, Cort D, Rodgers J, Burakoff R, DeSchryver-Keeskemeti K, Gmamlich T, Beeken W: Dietary supplementation with fish oil in ulcerative colitis. Ann Int Med 1992, 116:609-614.
36. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, et al.: Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomized controlled trial. Gut 1992, 33:922-928.
37. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996, 334:1557-1560.
38. Boyko EJ, Koepsell TD, Perera DR, Inui TS: Risk of ulcerative colitis among former and current cigarette smokers. N Eng J Med 1987, 316:707-710.
39. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, et al: Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 330:811-815.
40. Thomas GA, Rhodes J, Mani V, Williams GT, Newcombe RG, Russell MA, Feyerabend C: Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995, 332:988-992.
41. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP, et al.: Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997, 126:364-371.
42. Sadowska-Krowicka H, Mannick EE, Oliver PD, Sandoval M, Zhang XJ, Eloby-Childess S, et al.: Genistein and gut inflammation: role of nitric oxide. Proc Soc Exp Biol Med 1998, 217:351-357.
43. Ware JH, Wan XS, Newberne P, Kennedy AR: Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Dig Dis Sci 1999, 44:986-990.
44. Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C: Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophy 1995, 322:339-346.
45. Varilek GW, Yang F, Lee EY, Schweder D, McClain CJ: Green tea attenuates inflammation and severity of colitis in IL-2 deficient mice. Gastroenterology 1999, 116:A836.
46. Schaafsma G: State of the art concerning probiotic strains in milk products. IDF Nutr News 1996, 5:23-24.
47. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ: T cell receptor-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997, 150:91-97.
48. Sellon RK, Tonkonogy SL, Schultz M, Dieleman LA, Grenther W, Balish E, et al.: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin 10-deficient mice. Infect Immun 1998, 66:5224-5231. The authors demonstrate the role of enteric bacteria in the development of colitis.
49. Fabia R, Ar'Rajab A, Johansson ML, Andersson R, Willen R, Jeppsson B, et al.: Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993, 54:248-255.
50. Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J: Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 1997, 42:817-822.
51. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN: Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999, 116:1107-1114. This study demonstrates the protective role of lactobacilli in the evolution of colitis.
52. Schultz M, Veltcamp C, Dieleman LA, Wyrick PB, Tonkonogy SL, Sartor RB: Continuous feeding of Lactobacillus plantarium attenuates established colitis in interleukin-10 deficient mice. Gastroenterology 1998, 114:A1081.
53. Gionchetti P, Rizzello F, Venturi A, Matteuzzi D, Rossi M, Peruzzo S, et al.: Maintenance reatment of chronic pouchitis: a randomized, placebo controlled, double-blind trial with a new probiotic preparation. Gastroenterology 1998, 114:A985.
54. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11:853-858.